Free Trial
NASDAQ:DRMAW

Dermata Therapeutics (DRMAW) Stock Price, News & Analysis

$0.03 0.00 (0.00%)
As of 02/24/2025

About Dermata Therapeutics Stock (NASDAQ:DRMAW)

Key Stats

Today's Range
$0.03
$0.03
50-Day Range
$0.01
$0.03
52-Week Range
$0.01
$0.03
Volume
N/A
Average Volume
15,383 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Receive DRMAW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dermata Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DRMAW Stock News Headlines

See More Headlines

DRMAW Stock Analysis - Frequently Asked Questions

Dermata Therapeutics' stock was trading at $0.0107 on January 1st, 2025. Since then, DRMAW stock has increased by 178.5% and is now trading at $0.0298.
View the best growth stocks for 2025 here
.

Shares of DRMAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:DRMAW
Fax
N/A
Employees
8
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:DRMAW) was last updated on 2/25/2025 by MarketBeat.com Staff
From Our Partners